Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices

Midhun Malla, Jonathan M Loree, Pashtoon Murtaza Kasi, Aparna Raj Parikh, Midhun Malla, Jonathan M Loree, Pashtoon Murtaza Kasi, Aparna Raj Parikh

Abstract

There exists a tremendous opportunity in identifying and determining the appropriate predictive and prognostic biomarker(s) for risk stratification of patients with colorectal cancers (CRCs). Circulating tumor DNA (ctDNA) has emerged as a promising prognostic and possibly predictive biomarker in the personalized management of patients with CRCs. The disease is particularly suited to a liquid biopsy-based approach since there is a great deal of shedding of circulating tumor fragments (cells, DNA, methylation markers, etc). ctDNA has been shown to have several potential applications, including detecting minimal residual disease (MRD), monitoring for early recurrence, molecular profiling, and therapeutic response prediction. The utility of ctDNA has broadened from its initial use in the advanced/metastatic setting for molecular profiling and detection of acquired resistance mechanisms, toward identifying MRD, as well as early detection. Prospective studies such as CIRCULATE, COBRA, Dynamic II/III, and ACT3 are underway in the MRD setting to further understand how ctDNA may be used to inform clinical decision making using both tumor-informed and tumor-agnostic platforms. These prospective studies use ctDNA to guide management of patients with CRC and will be critical to help guide how and where ctDNA should or should not be used in clinical decision making. It is also important to understand that there are different types of ctDNA liquid biopsy platforms, each with advantages and disadvantages in different clinical indications. This review provides an overview of the current and evolving use of ctDNA in CRC.

Figures

FIG 1.
FIG 1.
Types of ctDNA platforms and their various clinical applications for patients with colorectal cancer. The utility of ctDNA has broadened from its initial use in the advanced/metastatic setting for molecular profiling and detection of acquired resistance mechanisms, toward identifying MRD, as well as early detection. ctDNA, circulating tumor DNA; EGFR, epidermal growth factor receptor; MRD, minimal residual disease; MSI, microsatellite instability; NGS, next-generation sequencing; NTRK, neurotrophic tyrosine receptor kinase; PCR, polymerase chain reaction; TMB, tumor mutational burden.
FIG 2.
FIG 2.
Risk of CRC recurrence in patients who have undergone curative-intent surgery and are ctDNA-positive.-. CRC, colorectal cancer; ctDNA, circulating tumor DNA; HR, hazard ratio.

References

    1. Ashworth TR: A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australas Med J 14:146-147, 1869
    1. Bettegowda C, Sausen M, Leary RJ, et al. : Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24, 2014
    1. Manca P, Corallo S, Lonardi S, et al. : SO-24 Circulating tumor DNA variant allelic fraction as a surrogate for disease burden estimation in patients with RAS wild-type metastatic colorectal cancer: A secondary endpoint of the VALENTINO study. Ann Oncol 32:S212, 2021
    1. Vidal J, Muinelo L, Dalmases A, et al. : Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol 28:1325-1332, 2017
    1. Osumi H, Shinozaki E, Takeda Y, et al. : Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer. Cancer Med 8:408-417, 2018
    1. Kagawa Y, Elez E, García-Foncillas J, et al. : Combined analysis of concordance between liquid and tumor tissue biopsies for RAS mutations in colorectal cancer with a single metastasis site: The METABEAM study. Clin Cancer Res 27:2515-2522, 2021
    1. Parikh AR, Leshchiner I, Elagina L, et al. : Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med 25:1415-1421, 2019
    1. Yoshino T: SCRUM-Japan GI-SCREEN: The nationwide cancer genome screening projects for gastrointestinal cancer in Japan. Ann Oncol 26:vii5, 2015
    1. Nakamura Y, Taniguchi H, Ikeda M, et al. : Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 26:1859-1864, 2020
    1. Overman MJ, Modak J, Kopetz S, et al. : Use of research biopsies in clinical trials: Are risks and benefits adequately discussed? J Clin Oncol 31:17-22, 2013
    1. Popper HH: Commentary on tumor heterogeneity. Transl Lung Cancer Res 5:433-435, 2016
    1. Morris LG, Riaz N, Desrichard A, et al. : Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7:10051-10063, 2016
    1. Diehl F, Schmidt K, Choti MA, et al. : Circulating mutant DNA to assess tumor dynamics. Nat Med 14:985-990, 2008
    1. Henriksen TV, Tarazona N, Reinert T, et al. : Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients. Clin Cancer Res 28:507-517, 2022
    1. Parikh AR, Van Seventer EE, Siravegna G, et al. : Minimal residual disease detection using a plasma-only circulating tumor DNA assay in colorectal cancer patients. Clin Cancer Res 27:5586-5594, 2021
    1. Tie J, Wang Y, Tomasetti C, et al. : Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8:346ra92, 2016
    1. Tie J, Cohen JD, Wang Y, et al. : Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol 5:1710-1717, 2019
    1. Henriksen TVV, Tarazona N, Frydendahl A, et al. : Serial circulating tumor DNA analysis to assess recurrence risk, benefit of adjuvant therapy, growth rate and early relapse detection in stage III colorectal cancer patients. J Clin Oncol 39, 2021. (suppl 15; abstr 3540)
    1. Overman MJ, Vauthey J-N, Aloia TA, et al. : Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence. J Clin Oncol 35, 2017. (suppl 15; abstr 3522)
    1. Tie J, Wang Y, Cohen J, et al. : Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases : A prospective cohort study. PLoS One 18:e1003620, 2021
    1. Chee B, Ibrahim F, Esquivel M, et al. : Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectal cancer (mCRC) following curative intent surgery or radiation. J Clin Oncol 39, 2021. (suppl 15; abstr 3565)
    1. Loupakis F, Sharma S, Derouazi M, et al. : Detection of molecular residual disease using personalized circulating tumor DNA assay in patients with colorectal cancer undergoing resection of metastases. JCO Precis Oncol 5:1166-1177, 2021
    1. Nimeiri H, Young A, Madison R, et al. : Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients undergoing surgical resection. J Clin Oncol 40, 2022. (suppl 4; abstr 187)
    1. Kotaka M, Shirasu H, Watanabe J, et al. : Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. J Clin Oncol 40, 2022. (suppl 4; abstr9)
    1. Reinert T, Henriksen TV, Christensen E, et al. : Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol 5:1124-1131, 2019
    1. Wilkinson NW, Yothers G, Lopa S, et al. : Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: Pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol 17:959-966, 2010
    1. André T, Boni C, Navarro M, et al. : Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
    1. Osterman E, Glimelius B: Recurrence risk after up-to-date colon cancer staging, surgery, and pathology: Analysis of the entire Swedish population. Dis Colon Rectum 61:1016-1025, 2018
    1. Chakrabarti S, Peterson CY, Sriram D, et al. : Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World J Gastrointest Oncol 12:808-832, 2020
    1. Wan JCM, Massie C, Garcia-Corbacho J, et al. : Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat Rev Cancer 17:223-238, 2017
    1. Siravegna G, Marsoni S, Siena S, et al. : Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 14:531-548, 2017
    1. Biagi JJ, Raphael MJ, Mackillop WJ, et al. : Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: A systematic review and meta-analysis. JAMA 305:2335-2342, 2011
    1. Henriksen TV, Reinert T, Christensen E, et al. : The effect of surgical trauma on circulating free DNA levels in cancer patients—implications for studies of circulating tumor DNA. Mol Oncol 14:1670-1679, 2020.
    1. Dasari A, Morris VK, Allegra CJ, et al. : CtDNA applications and integration in colorectal cancer: An NCI Colon and Rectal–Anal Task Forces whitepaper. Nat Rev Clin Oncol 17:757-770, 2020
    1. Henriksen TV, Tarazona N, Frydendahl A, et al. : Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res 14:1748-1753, 2021
    1. Taieb J, Taly V, Vernerey D, et al. : Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration. Ann Oncol 30:v867, 2019
    1. Dawson SJ, Tsui DW, Murtaza M, et al. : Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368:1199-1209, 2013
    1. Diaz LA, Jr, Williams RT, Wu J, et al. : The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537-540, 2012
    1. Siravegna G, Mussolin B, Buscarino M, et al. : Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21:795-801, 2015
    1. Parikh AR, Mojtahed A, Schneider JL, et al. : Serial CtDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers. Clin Cancer Res 26:1877-1885, 2020
    1. Tin A, Aushev V, Kalashnikova E, et al. : Correlation of variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors. Mol Oncol 15:57-66, 2021
    1. Andre T, Shiu KK, Kim TW, et al. : Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. J Clin Oncol 38, 2020. (suppl 18; abstr LBA4)
    1. Kasi PM, Budde G, Krainock M, et al. : Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA4 rescue in patients with mismatch repair deficient metastatic colorectal cancer. J Immunother Cancer 10:e003312, 2022
    1. Bratman SV, Yang SC, Iafolla MA, et al. : Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer 1:873-881, 2020
    1. Zhang Q, Luo J, Wu S, et al. : Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov 10:1842-1853, 2020
    1. Parseghian CM, Loree JM, Morris VK, et al. : Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge. Ann Oncol 30:243-249, 2019
    1. Murtaza M, Dawson SJ, Tsui DW, et al. : Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108-112, 2013
    1. Loree JM, Henry J, Raghav KPS, et al. : Serial circulating tumor DNA (CtDNA) monitoring in metastatic colorectal cancer (mCRC) reveals dynamic profile of actionable alterations. J Clin Oncol 39, 2021. (suppl 15; abstr 3572)
    1. Sartore-Bianchi A, Pietrantonio F, Lonardi S, et al. : Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial. J Clin Oncol 39, 2021. (suppl 15; abstr 3506)
    1. Morelli MP, Overman MJ, Dasari A, et al. : Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26:731-736, 2015
    1. Cremolini C, Rossini D, Dell’Aquila E, et al. : Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: A phase 2 single-arm clinical trial. JAMA Oncol 5:343-350, 2019
    1. Ma M, Zhu H, Zhang C, et al. : “Liquid biopsy”—CtDNA detection with great potential and challenges. Ann translational Med 3:235, 2015
    1. Diehl F, Schmidt K, Durkee KH, et al. : Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 135:489-498, 2008
    1. De Mattos-Arruda L, Mayor R, Ng CKY, et al. : Cerebrospinal fluid- derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6:8839, 2015
    1. Kimura H, Fujiwara Y, Sone T, et al. : EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 95:1390-1395, 2006
    1. Wang Y, Springer S, Mulvey CL, et al. : Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med 7:293ra104, 2015
    1. Reckamp KL, Melnikova VO, Karlovich C, et al. : A highly sensitive and Quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol 11:1690-1700, 2016
    1. Drusbosky L, Bilen MA, Azzi G, et al. : Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay. J Clin Oncol 39, 2021. (suppl 15; abstr 3040)
    1. Cohen S, Hook N, Krinshpun S, et al. : SO-34 Clinical experience of a personalized and tumor-informed circulating tumor DNA assay for minimal residual disease detection in oligometastatic colorectal cancer patients. Ann Oncol 31:S229, 2020
    1. Kasi PM, Dayyani F, Morris V, et al. : Tumor-informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced stage colorectal cancer (CRC-MRD Consortia). J Clin Oncol 38, 2020. (suppl 15; abstr 4108)
    1. Tarazona N, Henriksen TV, Carbonell-Asins JA, et al. : Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC. J Clin Oncol 38, 2020. (suppl 15; abstr 4009)
    1. Anandappa G, Starling N, Begum R, et al. : Minimal residual disease (MRD) detection with circulating tumor DNA (CtDNA) from personalized assays in stage II-III colorectal cancer patients in a UK multicenter prospective study (TRACC). J Clin Oncol 39, 2021. (suppl 3; abstr 102)
    1. Shirasu H, Taniguchi H, Watanabe J, et al. : O-11 Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan. Ann Oncol 32:S222-S223, 2021
    1. Vidal J, Casadevall D, Bellosillo B, et al. : Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: A biomarker study from the GEMCAD 1402 trial. Clin Cancer Res 27:2890-2898, 2021
    1. MolDX: Minimal Residual Disease Testing for Colorectal Cancer, 2021.
    1. Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage Cancer, 2021.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner